Artisan Partners Limited Partnership Invests $13.69 Million in Bruker Corporation $BRKR

Artisan Partners Limited Partnership purchased a new position in shares of Bruker Corporation (NASDAQ:BRKR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 421,201 shares of the medical research company’s stock, valued at approximately $13,685,000. Artisan Partners Limited Partnership owned 0.28% of Bruker at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in BRKR. Linden Thomas Advisory Services LLC lifted its stake in Bruker by 2.1% in the third quarter. Linden Thomas Advisory Services LLC now owns 19,669 shares of the medical research company’s stock worth $639,000 after purchasing an additional 396 shares during the last quarter. M&T Bank Corp raised its holdings in shares of Bruker by 2.7% in the second quarter. M&T Bank Corp now owns 15,580 shares of the medical research company’s stock worth $642,000 after buying an additional 411 shares during the period. Arizona State Retirement System lifted its stake in shares of Bruker by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 31,369 shares of the medical research company’s stock worth $1,019,000 after acquiring an additional 435 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in Bruker by 39.5% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,560 shares of the medical research company’s stock valued at $64,000 after acquiring an additional 442 shares during the period. Finally, Nisa Investment Advisors LLC grew its position in Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Insider Activity

In other news, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. This trade represents a 5.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 27.30% of the company’s stock.

Bruker Stock Down 2.2%

Shares of Bruker stock opened at $40.11 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The stock has a market cap of $6.09 billion, a price-to-earnings ratio of -267.40, a PEG ratio of 2.40 and a beta of 1.19. The firm’s 50-day moving average is $45.64 and its two-hundred day moving average is $40.85. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $56.22.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. During the same quarter in the prior year, the firm posted $0.76 EPS. The company’s revenue for the quarter was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts expect that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is -133.33%.

Analyst Ratings Changes

Several research firms have recently weighed in on BRKR. Rothschild & Co Redburn set a $60.00 target price on Bruker in a research report on Thursday, November 20th. JPMorgan Chase & Co. raised their price target on shares of Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. TD Cowen dropped their target price on shares of Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. Finally, Bank of America raised their target price on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Bruker has an average rating of “Hold” and a consensus target price of $50.38.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.